Lu et al. in 2023 mentioned that multiple ARID1A-related stomach cancer clinical trials were underway and that synthetic lethality combination for ARID1A-deficient stomach cancer might be inhibitors against PARP, PI3K, EZH2, and PD-L1 [70]. This evidence concerns the gene CD274 and gastric neoplasm.